Recent information on opioid susbstitution treatments
Tendances n° 65, OFDT, 6 p.
It is estimated that 120,000 people were being treated with OST in 2007, with a marked predominance of HDB, which made up 80% of the total (a specific French feature).
Almost 15 years after they were first marketed, the impact of OST in people with opiate dependency is clearly extremely positive, but cases of misuse have also occurred, making it necessary to monitor the prescription of these substances.
It was in this context that co-operation between CNAMTS and the OFDT was set up. The study described here is the third part of this work. This new study is based, for the first time, on the whole country rather than regional sites, from two representative samples of beneficiaries of the general scheme of French health insurance selected at random for the years 2006 and 2007. It sets out to describe both the methods of use of OST over these two years (levels of use, therapeutic associations) and also their intended uses (therapeutic or misuse), particularly from the length of treatments, and describes any abuse or misuse encountered.
Tiphaine Canarelli, Anaëlle Coquelin
Download the PDF file (149 Ko)
Drugs in Europe
What do the latest data tell us about the European drug market? What are the new trends in drug use among European adults and school students? What are the harms associated with drug use and what is being done to counter them? These and other questions are explored in the 2019 EMCDDA European Drug Report.
Country drug reports 2019
Developed by the EMCDDA, in cooperation with the Reitox national focal points, these graphic-rich reports cover: drug use and public health problems; drug policy and responses and drug supply.
The European Union and the drug phenomenon
The European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.